PDCD1 and neoplasm: Resistance mechanism to anti-PD-1 has been recently proposed to be associated with tumor-associated macrophages that could bypass the targeting of T cells [73] or with mutation in key signaling pathways such as JAK1/2 kinases inducing IFNγ lack of response [74,75].